Rhythm Pharmaceuticals, Inc.'s SEC filings document a commercial-stage biopharmaceutical company whose disclosures center on IMCIVREE (setmelanotide), MC4R pathway rare-disease indications and related clinical and regulatory milestones. Recent Form 8-K reports include operating results, product-revenue commentary, FDA and European regulatory updates for acquired hypothalamic obesity, and trial disclosures for programs such as TRANSCEND and EMANATE.
Rhythm's proxy materials and governance filings disclose board composition, director elections, executive compensation, equity awards and shareholder voting matters. Other current reports record director changes, Regulation FD materials, presentations and press releases, tying corporate governance and public-company reporting to the company's rare neuroendocrine disease portfolio.
RYTM Pharmaceuticals’ President and CEO David P. Meeker reported equity awards consisting of restricted stock units and stock options. On February 11, 2026, he received 71,900 restricted stock units, each representing the right to receive one share of common stock. These units vest 25% each on February 1, 2027, 2028, 2029 and 2030.
On the same date, he was also granted 107,850 stock options with an exercise price of $98.47 per share. These options vest in 16 substantially equal quarterly installments, based on completing each three full months of successive service after the grant date. Both awards are held directly.
Mazabraud Yann reported acquisition or exercise transactions in this Form 4 filing.
Pharmaceuticals, Inc. executive Yann Mazabraud, EVP and Head of International, reported receiving a grant of 23,350 restricted stock units on February 11, 2026. This was an award of derivative securities at a reported price of $0 per unit, held as direct ownership.
The restricted stock units give a contingent right to receive one share of common stock for each unit. They vest in four equal installments of 25% of the total grant on March 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030, and have no expiration date.
Rhythm Pharmaceuticals executive Jennifer Kayden Lee received new equity awards tied to her role as EVP, Head of North America. On February 11, 2026, she was granted 21,650 restricted stock units, each representing one share of common stock, and 32,500 stock options with a $98.47 exercise price.
The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029, and 2030 and have no expiration date. The stock options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date. All awards are held directly.
German Christopher Paul reported acquisition or exercise transactions in a Form 4 filing for RYTM. The filing lists transactions totaling 5,215 shares. Following the reported transactions, holdings were 5,215 shares.
Rhythm Pharmaceuticals’ Chief Scientific Officer Alastair Garfield received new equity awards. On February 11, 2026, he was granted 16,650 restricted stock units, each representing one share of common stock, and 25,000 stock options with an exercise price of $98.47 per share.
The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029 and 2030. The options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date.
Rhythm Pharmaceuticals’ Chief Human Resources Officer Pamela J. Cramer received new equity awards. On February 11, 2026, she was granted 11,650 restricted stock units, each representing one share of common stock. These RSUs vest in four equal 25% installments on February 1 of 2027, 2028, 2029, and 2030.
She was also granted stock options for 17,500 shares of common stock at an exercise price of $98.47 per share. These options vest in 16 substantially equal installments, based on completing each three full months of successive service after the grant date. All awards are held directly.
Rhythm Pharmaceuticals’ Chief Financial Officer Hunter C. Smith reported multiple open-market sales of common stock on February 10–12, 2026. These sales, executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025, left him holding 118,466 shares directly.
On February 11, 2026, Smith also received equity compensation in the form of 25,000 restricted stock units and stock options for 37,500 shares at an exercise price of $98.47. The RSUs vest in four equal annual installments from February 1, 2027 through February 1, 2030, while the options vest in 16 substantially equal quarterly installments after the grant date.
PRIMECAP Management Co. filed an amended Schedule 13G reporting its beneficial ownership of common stock of RYTM Pharmaceuticals, Inc. As of the event date, PRIMECAP reports beneficial ownership of 3,478,669 shares, representing 5.21% of the company’s outstanding class.
PRIMECAP has sole power to vote and dispose of all 3,478,669 shares, with no shared voting or dispositive power. The firm certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Rhythm Pharmaceuticals.
The Chief Financial Officer of a biopharmaceutical issuer filed a Form 4 showing open-market sales of common stock on February 4–5, 2026. On February 4, the officer sold 1,500 shares at a weighted average price of $104.7434, 1,000 shares at $106.604, and 747 shares at $107.6654. On February 5, the officer sold an additional 3,381 shares at $106.063.
After these transactions, the officer directly beneficially owned 125,537 shares of common stock. The filing notes that the sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 28, 2025, and that each reported price is a weighted average for multiple trades within the stated price ranges.
A person filing on behalf of RYTM has submitted a Form 144 notice covering a planned sale of 18,406 shares of common stock through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of February 5, 2026. The shares have an indicated aggregate market value of $1,987,295.82, compared with 66,736,056 shares of common stock outstanding. These shares were acquired as restricted stock units from the issuer on February 10, 2025. The form also notes a prior Rule 10b5-1 sale for Hunter Smith of 3,247 common shares on February 4, 2026, generating gross proceeds of $344,145.31.